{"meta":{"query_hash":"4468135ef0ab","filters":{"venue":"Current Cancer Drug Targets"},"cohort_total":37,"direct_labels_cover":0,"predictions_cover":37,"exported":37,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/4468135ef0ab","api":"https://metacan.xera.ac/api/v1/cohort?venue=Current+Cancer+Drug+Targets"},"results":[{"id":"W131285836","doi":"10.2174/156800907780058844","title":"Oncolytic Viruses: Whats Next?","year":2007,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Oncolytic virus; Exploit; Cancer; Biology; Computational biology; Virus; Computer science; Virology; Computer security; Genetics","score_opus":0.1284561124885577,"score_gpt":0.4518016595399557,"score_spread":0.323345547051398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W131285836","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001749931,0.99535197,0.000041445637,0.000019030549,0.002544019,0.0012373665,0.00022064125,0.000041693987,0.0003688554],"genre_scores_gemma":[0.000024440413,0.9946266,0.00003070291,0.00017651894,0.00274475,0.0005857764,0.00067760394,0.00019399858,0.0009396393],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962766,0.0002857864,0.0007369852,0.001151922,0.0005539353,0.0009947792],"domain_scores_gemma":[0.9979056,0.00004998913,0.00037710834,0.0011052632,0.00018733725,0.0003747151],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006244954,0.00079829677,0.0012623215,0.00026180784,0.00015236058,0.00011909586,0.0010569877,0.00042808827,0.0003990121],"category_scores_gemma":[0.00005932877,0.0007072112,0.0007903271,0.00041184595,0.00017612596,0.000011204332,0.00037355407,0.0007679769,0.0003604578],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015361066,0.00012326964,0.0000047670715,0.004836812,0.00026469448,0.000008769518,0.000025405245,0.0000043170744,0.0001534965,0.0000035678743,0.021727502,0.9726938],"study_design_scores_gemma":[0.00038191446,0.0002815396,6.432805e-7,0.0039253123,0.00023260481,0.000006671343,0.000008796121,0.0000029576963,0.001588251,0.000009374593,0.9928063,0.0007556104],"about_ca_topic_score_codex":0.000029525858,"about_ca_topic_score_gemma":0.00036120403,"teacher_disagreement_score":0.9719382,"about_ca_system_score_codex":0.00035651636,"about_ca_system_score_gemma":0.0019248585,"threshold_uncertainty_score":0.9995379},"labels":[],"label_agreement":null},{"id":"W1984087096","doi":"10.2174/156800907780058853","title":"Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus","year":2007,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Georgetown University; University of Pennsylvania","keywords":"Oncolytic virus; Medicine; Tolerability; Adverse effect; Desensitization (medicine); Regimen; Dosing; Toxicity; Pharmacology; Bolus (digestion); Phases of clinical research; Newcastle disease; Clinical trial; Internal medicine; Oncology; Virus; Cancer; Immunology; Receptor","score_opus":0.24429777598706143,"score_gpt":0.5522660217318367,"score_spread":0.30796824574477527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984087096","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.063032866,0.93395805,0.00029525434,0.0000053631625,0.0011785103,0.0009301921,0.0005712741,0.000014034474,0.000014481074],"genre_scores_gemma":[0.0066955723,0.99020517,0.00010117735,0.000027630535,0.0016547642,0.00016178648,0.0010121753,0.0000875807,0.000054115488],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996576,0.00041700556,0.0010986921,0.0009213699,0.0004418219,0.0005451255],"domain_scores_gemma":[0.99767154,0.000038625847,0.0006067949,0.0008902812,0.00021100498,0.00058173534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006475097,0.0004914505,0.0010147659,0.00013997301,0.0001058594,0.00003571557,0.0006220295,0.00025951883,0.00014036207],"category_scores_gemma":[0.00010632821,0.00046165497,0.0005180508,0.00024833097,0.00031630736,0.00001299287,0.00014644593,0.00043670987,0.00001008213],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001482206,0.0016100643,0.000013456835,0.0023729294,0.00010543193,0.000021383908,0.00007237735,0.000011470029,0.0009847247,0.0000017879917,0.00026374907,0.9930604],"study_design_scores_gemma":[0.001101696,0.0022744683,0.0000048507795,0.0019954052,0.00034349182,0.000008330154,0.000021870414,0.0001318725,0.006093967,0.000006094606,0.9874169,0.00060104067],"about_ca_topic_score_codex":0.00003264304,"about_ca_topic_score_gemma":0.0001823335,"teacher_disagreement_score":0.99245936,"about_ca_system_score_codex":0.0001675841,"about_ca_system_score_gemma":0.0034380092,"threshold_uncertainty_score":0.9997835},"labels":[],"label_agreement":null},{"id":"W1988669425","doi":"10.2174/156800912802429337","title":"Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma","year":2012,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CD44; Integrin; Extracellular matrix; Cell biology; Cell adhesion molecule; Cell adhesion; Fibronectin; Chemistry; Laminin; Adhesion; Cancer research; Biology; Cell; Biochemistry","score_opus":0.11710704615758474,"score_gpt":0.4100367581634505,"score_spread":0.2929297120058657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988669425","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006751259,0.99603057,0.000008850233,0.000020637766,0.0005036665,0.0022984024,0.00018163671,0.000043745702,0.00023737698],"genre_scores_gemma":[0.024096882,0.97366685,0.00008033166,0.000009442976,0.00035477625,0.00080127147,0.00071631855,0.00010808256,0.00016605336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964362,0.0003344209,0.0009857629,0.00063996145,0.00068227184,0.00092143274],"domain_scores_gemma":[0.99820834,0.00024268811,0.0005106678,0.00048024007,0.00015467049,0.00040336873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034254295,0.0006747801,0.0021656393,0.00049370347,0.0000702632,0.000018792458,0.00028383697,0.00022731573,0.0004904177],"category_scores_gemma":[0.00012258382,0.00049524556,0.0005592665,0.0004970111,0.00011392339,0.000116007024,0.00013955921,0.000806556,0.00015430525],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115017254,0.00066971564,0.0036395865,0.026901383,0.00034236326,0.000053203672,0.00014020663,0.000003703915,0.000025409512,0.000033209624,0.0002231311,0.96785307],"study_design_scores_gemma":[0.0026917858,0.00015936006,0.0016311273,0.030397452,0.0012038609,0.000019962261,0.0000610623,0.00023095905,0.00026190095,0.000032285465,0.9627145,0.00059573055],"about_ca_topic_score_codex":0.00043909682,"about_ca_topic_score_gemma":0.000072328716,"teacher_disagreement_score":0.9672573,"about_ca_system_score_codex":0.00054570765,"about_ca_system_score_gemma":0.001109597,"threshold_uncertainty_score":0.9997499},"labels":[],"label_agreement":null},{"id":"W1990604167","doi":"10.2174/156800908785699306","title":"Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer","year":2008,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Epigenetics; Malignancy; Esophageal cancer; Biology; Esophagus; Disease; Epigenetic therapy; Cancer; Cancer research; Carcinogenesis; Somatic evolution in cancer; Bioinformatics; Carcinoma; Medicine; Genetics; Pathology; Internal medicine; Gene; DNA methylation; Gene expression","score_opus":0.04657069195341299,"score_gpt":0.36571571210259707,"score_spread":0.31914502014918406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990604167","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030554493,0.99368113,0.0002111028,0.000022463688,0.0014466338,0.0010059045,0.0004988843,0.000015568574,0.000062833315],"genre_scores_gemma":[0.0024378502,0.994702,0.00016843178,0.000015582775,0.00081779587,0.00064407627,0.000837559,0.00010775021,0.00026897166],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99728775,0.00024891525,0.0008640505,0.0008558735,0.00029216177,0.00045125204],"domain_scores_gemma":[0.99828035,0.00004199461,0.0006638683,0.00057939225,0.00023169228,0.00020267903],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013779063,0.0006402807,0.0011658992,0.00017717792,0.00016964316,0.00002428542,0.000347906,0.00034094,0.00011862879],"category_scores_gemma":[0.00003777383,0.0005723895,0.00043461568,0.0002720987,0.00022734085,0.0000057661723,0.00014518756,0.00029233983,0.000005899424],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011959491,0.000109952416,0.00052552024,0.0017412376,0.00026853356,0.0000013404907,0.00013336654,0.000084355124,0.0010010913,0.000007545659,0.0013640533,0.99475104],"study_design_scores_gemma":[0.00040791061,0.000076185315,0.00053191005,0.0011870364,0.00017976383,0.000002187468,0.0000040895925,0.000013737426,0.008250888,0.00004105013,0.9887363,0.00056899193],"about_ca_topic_score_codex":0.00011915919,"about_ca_topic_score_gemma":0.00011287475,"teacher_disagreement_score":0.99418205,"about_ca_system_score_codex":0.00006217926,"about_ca_system_score_gemma":0.0008588034,"threshold_uncertainty_score":0.9996728},"labels":[],"label_agreement":null},{"id":"W1996963479","doi":"10.2174/156800912799277511","title":"The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases","year":2012,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Canada Research Chairs","keywords":"Medicine; Blood–brain barrier; Chemotherapy; Brain tumor; Brain metastasis; Radiation therapy; Oncology; Brain cancer; Cancer; Internal medicine; Pathology; Central nervous system; Metastasis","score_opus":0.05824059173052305,"score_gpt":0.3778907565616442,"score_spread":0.3196501648311212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996963479","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004849294,0.98930925,1.2306546e-7,0.0012223506,0.00068864954,0.003139707,0.0007040794,0.00002222321,0.00006434081],"genre_scores_gemma":[0.0034992283,0.9915388,0.000008320391,0.00010851278,0.00038816308,0.004026061,0.00023331144,0.00005790186,0.00013968945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99659413,0.0005867886,0.0009971772,0.000534091,0.0005903959,0.00069739396],"domain_scores_gemma":[0.99652493,0.00159712,0.00063600496,0.00089339964,0.00012296118,0.00022557036],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063253276,0.0007457798,0.0019873548,0.00021870821,0.00017745384,0.00004511555,0.0004408171,0.0001018856,0.00012025707],"category_scores_gemma":[0.0001984195,0.00033374748,0.0008749513,0.00058075297,0.00017450795,0.000091581336,0.00005740396,0.00032880023,0.00004416336],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019025996,0.0021228588,0.0013233812,0.005029379,0.0008338817,0.00007823426,0.001053792,0.0000035436638,0.00000179965,0.0002748329,0.0039280634,0.98533124],"study_design_scores_gemma":[0.0012738685,0.00020743493,0.00061671203,0.008395699,0.0043903207,0.000039151808,0.00006249934,0.000001381769,0.0001286855,0.000012676417,0.98459744,0.00027412095],"about_ca_topic_score_codex":0.00024298343,"about_ca_topic_score_gemma":0.00029022226,"teacher_disagreement_score":0.9850571,"about_ca_system_score_codex":0.00042071217,"about_ca_system_score_gemma":0.0006466778,"threshold_uncertainty_score":0.9999114},"labels":[],"label_agreement":null},{"id":"W2003470917","doi":"10.2174/156800908786733450","title":"Anti-Angiogenic Targets in the Treatment of Advanced Renal Cell Carcinoma","year":2008,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Health Canada; Memorial Sloan-Kettering Cancer Center","keywords":"Pazopanib; Temsirolimus; Sunitinib; Axitinib; Sorafenib; Everolimus; Medicine; Vascular endothelial growth factor; Cancer research; Renal cell carcinoma; Bevacizumab; Platelet-derived growth factor receptor; Angiogenesis; PI3K/AKT/mTOR pathway; Tyrosine-kinase inhibitor; Growth factor; Pharmacology; Internal medicine; Cancer; Biology; Signal transduction; VEGF receptors; Discovery and development of mTOR inhibitors; Receptor; Chemotherapy; Hepatocellular carcinoma","score_opus":0.05341450169617008,"score_gpt":0.340254233950875,"score_spread":0.28683973225470494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003470917","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011006768,0.9824006,0.000002097555,0.00006092109,0.001256636,0.0042279386,0.0004013098,0.00003854488,0.00060515857],"genre_scores_gemma":[0.012328872,0.98341054,0.00010274906,0.00001965634,0.0006575613,0.0018325581,0.0011024439,0.0001383447,0.0004072752],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952867,0.00039135257,0.0014540686,0.0011079094,0.0008595969,0.00090036774],"domain_scores_gemma":[0.9971185,0.00023119163,0.00089382165,0.0013299538,0.00015378465,0.0002727821],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014757799,0.0012383773,0.003919643,0.00055822544,0.00011334994,0.00001515725,0.00050976593,0.00024149036,0.00016255763],"category_scores_gemma":[0.000014920724,0.0007401014,0.0022165051,0.0008315026,0.0001912822,0.0000772718,0.000064617816,0.00051191787,0.00007767308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000095437164,0.0029596607,0.0013690231,0.012572362,0.0003774599,0.00070178695,0.0020992027,0.000019730673,0.000016310443,0.0000050761723,0.0055215163,0.9742624],"study_design_scores_gemma":[0.0027859986,0.000663529,0.0017929977,0.005236323,0.0024160526,0.00015649715,0.000051283318,0.0000042739025,0.00082960364,0.0000043262075,0.98548025,0.00057887635],"about_ca_topic_score_codex":0.00025563434,"about_ca_topic_score_gemma":0.00005874352,"teacher_disagreement_score":0.9799587,"about_ca_system_score_codex":0.0018877174,"about_ca_system_score_gemma":0.0014412228,"threshold_uncertainty_score":0.999505},"labels":[],"label_agreement":null},{"id":"W2010349266","doi":"10.2174/156800907780058862","title":"From ONYX-015 to Armed Vaccinia Viruses: The Education and Evolution of Oncolytic Virus Development","year":2007,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jennerex Biotherapeutics (Canada)","funders":"","keywords":"Vaccinia; Oncolytic virus; Virology; Virus; Biology; Medicine; Genetics","score_opus":0.05896900290161484,"score_gpt":0.41964664024537085,"score_spread":0.360677637343756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010349266","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022394411,0.9748068,0.00009111438,0.000035074998,0.0011486082,0.0012826711,0.00019043362,0.000009477414,0.00004141817],"genre_scores_gemma":[0.001664652,0.99582857,0.00012595844,0.0000868225,0.0010525363,0.00065657025,0.0003754588,0.0000615614,0.00014785155],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776584,0.00021729819,0.0006162301,0.00065513514,0.00036000984,0.0003855134],"domain_scores_gemma":[0.99862033,0.00005712314,0.0003336092,0.0005880612,0.00020479452,0.00019609192],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005121205,0.00040560425,0.00065193104,0.00017896597,0.00011616014,0.000028063138,0.0005223315,0.00018858527,0.00006662768],"category_scores_gemma":[0.00006572388,0.00030651098,0.00016846154,0.00029799115,0.00006945142,0.000004988769,0.00025933952,0.0002966283,0.000035575846],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022131963,0.00016708022,0.00003966067,0.0013169588,0.00019494286,2.5091597e-7,0.00032604623,0.0000033859394,0.0013641154,0.0000023709783,0.006821061,0.9895428],"study_design_scores_gemma":[0.0002202814,0.0001554863,0.00009439012,0.0022740338,0.00014923554,0.0000011149118,0.00005412146,0.000001579941,0.009330782,0.000016205926,0.98736334,0.0003394419],"about_ca_topic_score_codex":0.00030744734,"about_ca_topic_score_gemma":0.0014785521,"teacher_disagreement_score":0.9892034,"about_ca_system_score_codex":0.0005246993,"about_ca_system_score_gemma":0.0039759157,"threshold_uncertainty_score":0.9999387},"labels":[],"label_agreement":null},{"id":"W2011022421","doi":"10.2174/156800905774574020","title":"Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose","year":2005,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Pharmacology; Drug; Cancer; Drug development; Dosing; Pharmacokinetics; Pharmacodynamics; Cancer research; Internal medicine","score_opus":0.019165005628215513,"score_gpt":0.3107667388099772,"score_spread":0.2916017331817617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011022421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21261242,0.7848227,0.00009797842,0.0000635951,0.00070017396,0.0010617339,0.0006069493,0.00002572834,0.000008739017],"genre_scores_gemma":[0.054556943,0.942889,0.0005015159,0.00007411564,0.00079246,0.00042727427,0.00047301297,0.00013183766,0.00015388813],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964554,0.00025488972,0.00058125274,0.0016468009,0.00023417121,0.00082752923],"domain_scores_gemma":[0.99830765,0.00003995025,0.00040673642,0.0005789446,0.000121878715,0.00054483884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033851457,0.0010575091,0.0014895382,0.00022613072,0.0002113085,0.00009519922,0.00036012335,0.00042196646,0.00004334475],"category_scores_gemma":[0.000037883307,0.00092332036,0.00048459842,0.00027298843,0.00026119174,0.000020235879,0.0006527365,0.00032469456,0.000007641909],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014801417,0.00009514067,0.00032281765,0.0030121831,0.00057142845,0.00002519962,0.00007008511,0.000014719392,0.02055265,9.871003e-7,0.0034955877,0.9716912],"study_design_scores_gemma":[0.0009674932,0.00015122782,0.00049910013,0.0016699343,0.0008946509,0.000022645496,0.000019225603,0.000100590616,0.0155505845,0.0000019799168,0.97863,0.0014925867],"about_ca_topic_score_codex":0.0000935866,"about_ca_topic_score_gemma":0.000050629722,"teacher_disagreement_score":0.9751344,"about_ca_system_score_codex":0.00010853731,"about_ca_system_score_gemma":0.00023573122,"threshold_uncertainty_score":0.99932176},"labels":[],"label_agreement":null},{"id":"W2027556747","doi":"10.2174/156800910791859452","title":"Antisense Treatment in Human Prostate Cancer and Melanoma","year":2010,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; Western University","funders":"Canadian Institutes of Health Research; Francis Crick Institute","keywords":"Prostate cancer; Antisense therapy; Clusterin; Cancer; Cancer research; RNA; Medicine; Prostate; Biology; Internal medicine; Gene; Apoptosis; Locked nucleic acid; Genetics","score_opus":0.055797279390798975,"score_gpt":0.4177648667764648,"score_spread":0.3619675873856658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027556747","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015584615,0.9779567,1.5700293e-7,0.00015634613,0.002454985,0.0028073096,0.000828857,0.00006112631,0.00014987939],"genre_scores_gemma":[0.00033358566,0.9942616,0.000026345559,0.00002972514,0.0007508234,0.0029989567,0.00044233032,0.00011118267,0.0010454479],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99747145,0.00012386478,0.0007056222,0.0009136544,0.00021144835,0.00057394267],"domain_scores_gemma":[0.9986181,0.000059761755,0.00035342117,0.00056684756,0.00006630158,0.00033553247],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012555906,0.00070079876,0.0022651425,0.0003530004,0.00008035255,0.00002517221,0.00013352884,0.00024874337,0.00033256295],"category_scores_gemma":[0.000024467221,0.0005400537,0.0003112754,0.0002158262,0.00020245419,0.00004731007,0.00015110798,0.000712981,0.000024469247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032922297,0.00027656613,0.005272986,0.0176127,0.00011170984,0.000300242,0.00045805334,2.8614244e-7,0.000010830475,0.0000082649585,0.001219788,0.9746956],"study_design_scores_gemma":[0.0016372788,0.00007395347,0.0014880201,0.017400699,0.0013955206,0.000085912936,0.000008541989,0.00000426311,0.000014037741,0.000015618438,0.9774153,0.00046085336],"about_ca_topic_score_codex":0.00049844023,"about_ca_topic_score_gemma":0.0014171242,"teacher_disagreement_score":0.9761955,"about_ca_system_score_codex":0.0008238391,"about_ca_system_score_gemma":0.00089691085,"threshold_uncertainty_score":0.9997051},"labels":[],"label_agreement":null},{"id":"W2028643899","doi":"10.2174/1568009043481542","title":"Transforming Growth Factor-β Superfamily: Evaluation as Breast Cancer Biomarkers and Preventive Agents","year":2004,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"SMAD; Transforming growth factor; Smad2 Protein; Signal transduction; Growth differentiation factor; Breast cancer; Cancer research; Receptor; Biology; Transforming growth factor beta; Cancer; Cell biology; Bone morphogenetic protein; Biochemistry; Genetics; Gene","score_opus":0.04984810400057648,"score_gpt":0.38378748875309443,"score_spread":0.33393938475251794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028643899","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010327641,0.9838514,0.00006119399,0.00002363169,0.001582807,0.001783944,0.0022931504,0.00003224261,0.000044031007],"genre_scores_gemma":[0.009632625,0.9860779,0.000031630043,0.000022804456,0.000611401,0.0012530575,0.0021450527,0.000119027856,0.000106517946],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969123,0.00027160507,0.0006132482,0.001107858,0.0005480046,0.00054696715],"domain_scores_gemma":[0.99864155,0.000024765817,0.00036235846,0.0003911625,0.00029322118,0.00028692622],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025642692,0.0007602551,0.00087003096,0.00015814745,0.00018725016,0.00006733712,0.0003908013,0.00030065124,0.000402166],"category_scores_gemma":[0.000056560966,0.00069214375,0.0004853675,0.00020021561,0.00015156891,0.000021793952,0.00013497996,0.00028223958,0.000020112382],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005078938,0.00015625515,0.00041227057,0.0141387135,0.0009987847,0.000001624071,0.00026960383,0.000015743235,0.00023388519,0.0000031800037,0.0014517729,0.9822674],"study_design_scores_gemma":[0.0010156551,0.000029177398,0.0004933438,0.019421134,0.0021705523,0.000015970048,0.00002552572,0.0000047277817,0.0011093182,0.00004709469,0.9745416,0.0011259142],"about_ca_topic_score_codex":0.00030619837,"about_ca_topic_score_gemma":0.0001529101,"teacher_disagreement_score":0.98114145,"about_ca_system_score_codex":0.0004948856,"about_ca_system_score_gemma":0.0024416537,"threshold_uncertainty_score":0.99955297},"labels":[],"label_agreement":null},{"id":"W2032167680","doi":"10.2174/15680096113139990076","title":"P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives","year":2013,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":392,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"P-glycoprotein; Multiple drug resistance; Efflux; Pharmacology; Drug resistance; Cancer cell; Chemotherapy; Drug; Cancer; Medicine; Cancer research; Biology; Internal medicine; Biochemistry","score_opus":0.042917764602676295,"score_gpt":0.35926490706292274,"score_spread":0.3163471424602464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032167680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043306162,0.9878827,0.00032278954,0.00021325354,0.0019916338,0.008233127,0.00069104147,0.00010515284,0.0001272418],"genre_scores_gemma":[0.00035220856,0.9844238,0.0012444685,0.000026680951,0.0019937058,0.010483457,0.00072086003,0.00018896915,0.00056581054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99569863,0.00014917205,0.0010110402,0.0015046675,0.00057578855,0.001060688],"domain_scores_gemma":[0.9981342,0.00007405932,0.0006490892,0.0005087486,0.00025468797,0.00037924259],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033007818,0.0010734447,0.0025942381,0.0004844235,0.00021434539,0.00007816291,0.0001971774,0.00033170264,0.00013268655],"category_scores_gemma":[0.000018056433,0.00083647127,0.0006359047,0.00053988013,0.00017478973,0.00024588133,0.000056338413,0.0013165984,0.000006231051],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019615139,0.00052414637,0.00007398701,0.07531779,0.00020761482,0.000006803853,0.003468987,0.0000014253997,0.000008393488,0.0015755111,0.0007363979,0.9178828],"study_design_scores_gemma":[0.0023676264,0.000036233385,0.0000980665,0.033404585,0.0011032122,0.000003747056,0.00094494,0.00004294843,0.000036613517,0.0004734914,0.96060055,0.000887962],"about_ca_topic_score_codex":0.00023319462,"about_ca_topic_score_gemma":0.000490595,"teacher_disagreement_score":0.9598642,"about_ca_system_score_codex":0.0014561533,"about_ca_system_score_gemma":0.0012758496,"threshold_uncertainty_score":0.9994086},"labels":[],"label_agreement":null},{"id":"W2032199025","doi":"10.2174/1568009023333926","title":"Mutant Epidermal Growth Factor Receptors as Targets for Cancer Therapy","year":2002,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Receptor; Epidermal growth factor receptor; Epidermal growth factor; Cancer research; Extracellular; Biology; Tyrosine kinase; Epitope; Cancer; Receptor tyrosine kinase; Cancer cell; Mutant; Growth factor receptor; Mutation; Growth factor receptor inhibitor; Antibody; Cell biology; Immunology; Biochemistry; Genetics; Gene","score_opus":0.1673419595737975,"score_gpt":0.45933838070023336,"score_spread":0.29199642112643587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032199025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004072738,0.97253066,0.00003859626,0.0013877968,0.013688733,0.008563158,0.0029452178,0.00028058555,0.00052452256],"genre_scores_gemma":[0.00003446104,0.9745407,0.00014735955,0.00035086562,0.00643283,0.012565389,0.0007473466,0.0005821708,0.0045988397],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914201,0.00045578048,0.0018537529,0.0021799747,0.0017381926,0.0023522386],"domain_scores_gemma":[0.9950316,0.0005784906,0.00097423396,0.0012332166,0.0009497646,0.0012327126],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006487587,0.001786817,0.0048086112,0.0007336297,0.0003696609,0.00012200729,0.0011111015,0.0006787755,0.015174318],"category_scores_gemma":[0.00046521972,0.0013875364,0.002107522,0.0010207915,0.00034278003,0.00022570549,0.00023828626,0.0023775122,0.0005379965],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011578918,0.00031793144,0.00013955518,0.03265094,0.0007627598,0.00004061937,0.0004412232,7.320617e-7,0.0000049696296,0.000032314187,0.16758469,0.7979085],"study_design_scores_gemma":[0.001950321,0.00023175181,0.000014921014,0.026643394,0.00078290555,0.00003705114,0.00001823144,0.000029288247,0.0003478258,0.000062571424,0.9685433,0.001338427],"about_ca_topic_score_codex":0.000868723,"about_ca_topic_score_gemma":0.00011962255,"teacher_disagreement_score":0.80095863,"about_ca_system_score_codex":0.003578826,"about_ca_system_score_gemma":0.0046423967,"threshold_uncertainty_score":0.99992406},"labels":[],"label_agreement":null},{"id":"W2048425980","doi":"10.2174/1568009043481551","title":"Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications","year":2004,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Signal transduction; Biology; Cancer research; Cancer cell; Apoptosis; Cell biology; Programmed cell death; Cancer; Kinase; Cell signaling; Genetics","score_opus":0.03671337346671952,"score_gpt":0.327231160591954,"score_spread":0.29051778712523446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048425980","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001965801,0.99636364,0.00011758152,0.00016345578,0.00058013,0.00068360247,0.00011423217,0.000004229239,0.000007336684],"genre_scores_gemma":[0.035538018,0.96348345,0.000009726397,0.000028569177,0.0003290903,0.00038937086,0.00017440433,0.000027425625,0.000019917064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99886096,0.00013528274,0.00024036548,0.00043806303,0.00007844038,0.00024688046],"domain_scores_gemma":[0.99956363,0.000020319338,0.00014467824,0.0002035738,0.000026203501,0.000041618576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021901926,0.00028898456,0.00042288308,0.000085964704,0.0000742767,0.000036773537,0.00016515679,0.00014911203,0.000010449175],"category_scores_gemma":[0.0000022659945,0.00018610388,0.00008650067,0.00013375869,0.0000570201,0.0000035473863,0.00007468033,0.00020853916,4.1276698e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004951237,0.00005237106,0.000026226951,0.0026099365,0.00004668499,5.6124986e-7,0.0002808255,0.000103999635,0.004803753,0.000082194674,0.000019500925,0.991969],"study_design_scores_gemma":[0.00073770987,0.000054169654,0.0006263402,0.0054508066,0.00036641414,0.00001099954,0.00013921216,0.00006650881,0.001957586,0.00062075193,0.98921824,0.0007512399],"about_ca_topic_score_codex":0.00013409398,"about_ca_topic_score_gemma":0.0009815148,"teacher_disagreement_score":0.99121773,"about_ca_system_score_codex":0.000060439528,"about_ca_system_score_gemma":0.00017287182,"threshold_uncertainty_score":0.7589096},"labels":[],"label_agreement":null},{"id":"W2052792754","doi":"10.2174/1568009043332989","title":"Novel Approaches for Targeted Cancer Therapy","year":2004,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research","keywords":"Cancer; Cancer therapy; Targeted therapy; Medicine; Internal medicine","score_opus":0.18711714940376617,"score_gpt":0.41402475167517727,"score_spread":0.2269076022714111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052792754","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004326785,0.9823189,0.0029307879,0.0004048204,0.005124669,0.00627876,0.0025708135,0.00030524164,0.00006172036],"genre_scores_gemma":[0.000011614112,0.97611964,0.0021639871,0.00015585836,0.0036525237,0.015237819,0.0012812013,0.00046043054,0.0009169336],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953982,0.00006285639,0.0011289913,0.00155639,0.00063448516,0.0012190307],"domain_scores_gemma":[0.99718875,0.00014216654,0.00096153916,0.00093533116,0.00032628851,0.00044590764],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00024211507,0.0014712153,0.0037638803,0.00039273873,0.00022749389,0.00005198357,0.00058822014,0.00039388755,0.00046449315],"category_scores_gemma":[0.000041398944,0.001137911,0.0015809748,0.00066768937,0.00026697156,0.00020234166,0.00010405832,0.0010599759,0.000030310528],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022042824,0.00046954546,0.000009277798,0.044843324,0.001194346,0.0000027440778,0.00035019292,0.00006383635,0.000010804549,0.00015819265,0.0015425204,0.9511348],"study_design_scores_gemma":[0.0041185985,0.0000721308,0.000014195351,0.04086665,0.0014738258,0.000029315841,0.0000255461,0.00001878041,0.00011002129,0.0001677132,0.95198965,0.0011135533],"about_ca_topic_score_codex":0.00016433894,"about_ca_topic_score_gemma":0.000047615253,"teacher_disagreement_score":0.95044714,"about_ca_system_score_codex":0.0024795742,"about_ca_system_score_gemma":0.004196882,"threshold_uncertainty_score":0.9998037},"labels":[],"label_agreement":null},{"id":"W2058472600","doi":"10.2174/1568009054629672","title":"Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway","year":2005,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"National Cancer Institute; Terry Fox Foundation","keywords":"Ubiquitin ligase; Carcinogenesis; Hypoxia-inducible factors; Biology; Cancer research; Ubiquitin; Transcription factor; Vascular endothelial growth factor; Angiogenesis; Tumor suppressor gene; HIF1A; Cell biology; Cancer; Gene; Genetics; VEGF receptors","score_opus":0.039265318781170046,"score_gpt":0.3508890844591312,"score_spread":0.31162376567796113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058472600","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025153448,0.98251766,0.00013553085,0.00024155425,0.015227455,0.0010232452,0.00045638529,0.000048242433,0.00009837486],"genre_scores_gemma":[0.000086496046,0.98209894,0.00027910416,0.00032754362,0.015145448,0.00034571977,0.0010920885,0.00017537235,0.00044929457],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99598587,0.00039400443,0.0009096546,0.0014106071,0.00048306707,0.00081682514],"domain_scores_gemma":[0.9974855,0.00006481388,0.00066432136,0.0012522441,0.0002964454,0.00023665202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036093127,0.0010922903,0.0018700605,0.00011719256,0.00033279322,0.000084278254,0.000863571,0.00037696116,0.00005402446],"category_scores_gemma":[0.00014083591,0.00077801466,0.0011216883,0.0002662967,0.00025162817,0.000011205803,0.00064854044,0.00073386804,0.000060527796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013418907,0.00004783618,9.818785e-7,0.0014497481,0.0008966812,0.0000038615403,0.0005617073,0.00002221166,0.00052935886,0.000017709239,0.03921061,0.9572459],"study_design_scores_gemma":[0.00036154248,0.000017600212,0.0000023289842,0.0027844831,0.0009798015,0.0000057046464,0.000087123866,0.0000061504,0.0014209573,0.00008244594,0.99332255,0.00092933624],"about_ca_topic_score_codex":0.0002533046,"about_ca_topic_score_gemma":0.0007096768,"teacher_disagreement_score":0.95631653,"about_ca_system_score_codex":0.00029393504,"about_ca_system_score_gemma":0.0009475246,"threshold_uncertainty_score":0.9994671},"labels":[],"label_agreement":null},{"id":"W2061342795","doi":"10.2174/156800906777723976","title":"Radiation-Induced Bystander and other Non-Targeted Effects: Novel Intervention Points in Cancer Therapy?","year":2006,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canada Research Chairs; Irish Research Council; Science Foundation Ireland; Technological University Dublin; National Science Foundation","keywords":"Bystander effect; DNA damage; Radiation therapy; Cancer research; Cancer; Cancer cell; Medicine; Apoptosis; Biology; Immunology; DNA; Genetics; Internal medicine","score_opus":0.04054962463183979,"score_gpt":0.38925589363662094,"score_spread":0.34870626900478113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061342795","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025025296,0.98965853,0.000094480376,0.00016641703,0.0031822168,0.003938447,0.00028145514,0.000091197595,0.0000847011],"genre_scores_gemma":[0.0020250937,0.99365044,0.00005588739,0.00019468591,0.001117805,0.002078766,0.00042045128,0.00018820378,0.00026868394],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966915,0.00027095916,0.0010425759,0.00092036056,0.00050324487,0.00057136046],"domain_scores_gemma":[0.9981027,0.00026455804,0.00080944964,0.00046265827,0.00013851342,0.00022208657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005195765,0.00082431064,0.0021207598,0.00068324636,0.00007951839,0.00005536285,0.00021017726,0.00038336086,0.00020520252],"category_scores_gemma":[0.00010669624,0.00068437017,0.00053299963,0.00063033757,0.000062674815,0.00019655112,0.00005592345,0.0009227481,0.000023476783],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051964562,0.0005052198,0.0039505796,0.024854919,0.0004092234,0.000007823291,0.0002974097,0.0000056781096,0.00003360245,0.000009653471,0.007365907,0.962508],"study_design_scores_gemma":[0.0059299017,0.00012280399,0.004953772,0.03456322,0.00075893366,0.000008560456,0.0000069233247,0.00014689699,0.00012887105,0.000013608014,0.9526556,0.0007108866],"about_ca_topic_score_codex":0.0013038995,"about_ca_topic_score_gemma":0.00044701737,"teacher_disagreement_score":0.9617971,"about_ca_system_score_codex":0.0012049798,"about_ca_system_score_gemma":0.00056398736,"threshold_uncertainty_score":0.9995608},"labels":[],"label_agreement":null},{"id":"W2065979573","doi":"10.2174/156800911795538129","title":"Redox Environment and its Meaning for Breast Cancer Cells Fate","year":2011,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Free Radicals and Antioxidants","field":"Chemistry","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Redox; Cell biology; Intracellular; Oxidative stress; Signal transduction; Biology; Biochemistry; Chemistry","score_opus":0.046470419954510955,"score_gpt":0.3082267230743886,"score_spread":0.26175630311987763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065979573","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003630756,0.9912784,0.0000133892845,0.00003214219,0.0015089278,0.0004943964,0.006164694,0.00006140528,0.0004103088],"genre_scores_gemma":[0.00013271834,0.9957748,0.000049444043,0.0000127763005,0.0013945923,0.0010985864,0.00012718778,0.00014468358,0.0012651846],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997413,0.000032949487,0.0006715567,0.00096183695,0.0002523221,0.00066835113],"domain_scores_gemma":[0.9986222,0.000060707178,0.00058369414,0.00037249367,0.000042958975,0.0003179815],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013638927,0.00074021326,0.0014673513,0.00006982059,0.00017746408,0.000049495644,0.00043694672,0.0002492861,0.003014915],"category_scores_gemma":[0.000007005374,0.00061839115,0.00046867036,0.000067367284,0.00009177002,0.000103159895,0.00019777943,0.00051987777,0.00005085759],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009194112,0.000078518395,0.000008789027,0.039718002,0.00020667246,0.000002874202,0.00010355274,0.000001800053,0.000099270066,0.0001098378,0.005271589,0.95438987],"study_design_scores_gemma":[0.0003530947,0.000004071122,0.0000026442804,0.02140086,0.00082714326,0.000008237094,0.0000068928375,0.00005316833,0.0006420197,0.000043019973,0.97593176,0.00072709605],"about_ca_topic_score_codex":0.000065468856,"about_ca_topic_score_gemma":0.000017444574,"teacher_disagreement_score":0.97066015,"about_ca_system_score_codex":0.00033969316,"about_ca_system_score_gemma":0.00026047765,"threshold_uncertainty_score":0.99962676},"labels":[],"label_agreement":null},{"id":"W2071527358","doi":"10.2174/156800906777441753","title":"Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines","year":2006,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Multiple drug resistance; Inflammation; Proinflammatory cytokine; P-glycoprotein; Biology; Drug resistance; ATP-binding cassette transporter; Efflux; Cancer; Mechanism (biology); Cancer research; Immunology; Pharmacology; Transporter; Gene","score_opus":0.027960139299460684,"score_gpt":0.32850020099233623,"score_spread":0.30054006169287556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071527358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005498215,0.99371797,0.00014437312,0.00005757212,0.0020778133,0.0021475458,0.00083627505,0.00014103866,0.00082240906],"genre_scores_gemma":[0.00011786337,0.9826791,0.00031595625,0.000008551454,0.00076656847,0.0005643956,0.002321956,0.00015273366,0.013072853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99627745,0.00009530692,0.0014669129,0.00083026284,0.00079003884,0.0005400205],"domain_scores_gemma":[0.9975774,0.000054179578,0.0011659617,0.0007168052,0.0002887476,0.00019685077],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029172082,0.0007805781,0.0025847682,0.00028619016,0.0001034622,0.000016141546,0.0003101277,0.00030545102,0.00015475215],"category_scores_gemma":[0.000018811372,0.00061519595,0.00085699896,0.00045266602,0.00017435143,0.00011804266,0.000036224537,0.0005878141,0.000022307297],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012308074,0.00035636022,0.00018338661,0.1809367,0.00030099103,0.000019152914,0.00013706017,0.0000037591826,0.00012696465,0.0003033793,0.1439376,0.6735716],"study_design_scores_gemma":[0.00072299666,0.000010966013,0.00009577308,0.04662219,0.0014678075,0.0000024136052,0.000005063429,0.0000067486826,0.0006620236,0.00009076802,0.9497757,0.00053754577],"about_ca_topic_score_codex":0.00003376313,"about_ca_topic_score_gemma":0.00017368516,"teacher_disagreement_score":0.8058381,"about_ca_system_score_codex":0.00040485445,"about_ca_system_score_gemma":0.0007891852,"threshold_uncertainty_score":0.9996299},"labels":[],"label_agreement":null},{"id":"W2071672251","doi":"10.2174/1568009043333005","title":"Targeting Translation for Treatment of Cancer - A Novel Role for IRES?","year":2004,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Internal ribosome entry site; Translation (biology); Untranslated region; Biology; Eukaryotic translation; Cell biology; Protein biosynthesis; Cancer cell; Cancer; Cancer research; Messenger RNA; Genetics; Gene","score_opus":0.07399969090101047,"score_gpt":0.3989401575790323,"score_spread":0.3249404666780218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071672251","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003835143,0.98271555,0.008424952,0.000043738568,0.0010691696,0.0027525504,0.0049312264,0.000011367848,0.000013111805],"genre_scores_gemma":[0.00014094923,0.9829284,0.0012733387,0.0000061019555,0.0011635693,0.010832968,0.003348791,0.00008551858,0.00022037848],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827385,0.000022284237,0.000595792,0.0006408867,0.00011677863,0.00035038553],"domain_scores_gemma":[0.99882114,0.000028509832,0.00054229755,0.00032654722,0.00020168845,0.00007983986],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00009401311,0.00042833114,0.0008769398,0.00007577043,0.00011456485,0.000017712926,0.0002149932,0.0001988809,0.000021155733],"category_scores_gemma":[0.000013674151,0.0003601451,0.00075438904,0.000105257954,0.00005073653,0.000005727705,0.00001629815,0.000049054604,7.547097e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053425723,0.00023803629,0.0000055375995,0.009107772,0.0003114949,2.779222e-8,0.000103370265,0.0003882387,0.0013065814,0.000049374055,0.0008466773,0.9875895],"study_design_scores_gemma":[0.0012318712,0.00011675043,0.0000015900848,0.0025757104,0.00082150433,3.293835e-7,0.000011918278,0.0001008426,0.001955829,0.000029837845,0.99277544,0.0003784045],"about_ca_topic_score_codex":0.00014614275,"about_ca_topic_score_gemma":0.0001169158,"teacher_disagreement_score":0.99192876,"about_ca_system_score_codex":0.00029478548,"about_ca_system_score_gemma":0.0010986428,"threshold_uncertainty_score":0.999885},"labels":[],"label_agreement":null},{"id":"W2098122970","doi":"10.2174/156800910791208571","title":"Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent","year":2010,"lang":"en","type":"article","venue":"Current Cancer Drug Targets","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Poly ADP ribose polymerase; Gene silencing; PARP inhibitor; Temozolomide; Cancer research; Biology; Chemistry; Molecular biology; Polymerase; Biochemistry; DNA; Glioma; Gene","score_opus":0.02492817481694091,"score_gpt":0.3460347325329664,"score_spread":0.3211065577160255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098122970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922184,0.001916129,0.00029503336,0.0025948763,0.00089268,0.0015822253,0.0003260765,0.00008961488,0.00008498015],"genre_scores_gemma":[0.99683374,0.00027480978,0.00085089,0.00075618905,0.0007216307,0.000461148,0.000026478625,0.000041376825,0.000033751592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716574,0.00027242742,0.0005699477,0.0008504005,0.0005064321,0.0006350256],"domain_scores_gemma":[0.99822736,0.00033227104,0.00031177857,0.00025754666,0.00023847015,0.0006325534],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006357144,0.00043266892,0.0008356595,0.0003688657,0.00012340827,0.000022593995,0.0001033392,0.00013023063,0.00027100282],"category_scores_gemma":[0.00028554563,0.00041257506,0.000131353,0.0007874166,0.00017126136,0.00020941766,0.00013011959,0.00085440837,0.00001434337],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016914025,0.00080068683,0.007591046,0.00014688319,0.000060404825,0.000036111385,0.0013794091,0.000064649714,0.95239556,0.000005398167,0.0022058224,0.033622652],"study_design_scores_gemma":[0.0031589763,0.00023607023,0.041735128,0.00046868564,0.00010350189,0.000013006419,0.00011177949,0.00033058636,0.9527244,0.00003619867,0.0006872045,0.00039449002],"about_ca_topic_score_codex":0.0017553438,"about_ca_topic_score_gemma":0.00048784466,"teacher_disagreement_score":0.03414408,"about_ca_system_score_codex":0.00048100186,"about_ca_system_score_gemma":0.00036079748,"threshold_uncertainty_score":0.99983263},"labels":[],"label_agreement":null},{"id":"W2100388782","doi":"10.2174/156800911793743600","title":"Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)","year":2010,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Cancer Foundation","funders":"","keywords":"Gemcitabine; Medicine; Internal medicine; Oncology; Regimen; Univariate analysis; Biliary tract; Nucleoside transporter; Cancer; Gastroenterology; Multivariate analysis; Transporter","score_opus":0.0264076660779159,"score_gpt":0.33258992787752717,"score_spread":0.3061822617996113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100388782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13088048,0.8645997,0.000035922636,0.000070745,0.0008244791,0.0015099358,0.00201435,0.000024587847,0.000039775823],"genre_scores_gemma":[0.047275834,0.9461003,0.00010571123,0.0001695522,0.0014644155,0.0016375035,0.0023511476,0.0002692564,0.0006263079],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967619,0.00025313452,0.0008117523,0.001127029,0.00038582875,0.0006603109],"domain_scores_gemma":[0.99850124,0.000035163368,0.00039885976,0.00061401055,0.00015927535,0.0002914329],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002994201,0.00080534676,0.0012012853,0.00025735836,0.000104623585,0.000037819627,0.0005575802,0.00036751348,0.00031845973],"category_scores_gemma":[0.000029325905,0.0006243683,0.00033813054,0.00034169763,0.00010169114,0.0000222523,0.00012454802,0.00079675525,0.000008025615],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003101319,0.0028225232,0.057878543,0.0130118225,0.001227379,0.000083533254,0.0018051377,0.0003532727,0.0013990697,0.000017641887,0.08291194,0.8353878],"study_design_scores_gemma":[0.0013643645,0.00025601094,0.01232255,0.0058414578,0.0003582343,0.0000014597325,0.000008120375,0.0000014917874,0.00029218136,0.000004295931,0.97865784,0.00089197606],"about_ca_topic_score_codex":0.000094404,"about_ca_topic_score_gemma":0.00018694243,"teacher_disagreement_score":0.89574593,"about_ca_system_score_codex":0.00014971655,"about_ca_system_score_gemma":0.0009626781,"threshold_uncertainty_score":0.99962074},"labels":[],"label_agreement":null},{"id":"W2107103889","doi":"10.2174/156800909789760393","title":"Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy","year":2009,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Comprehensive Cancer Network","keywords":"Multiple myeloma; Medicine; Bone disease; Disease; Current (fluid); Intensive care medicine; Bioinformatics; Osteoporosis; Internal medicine; Biology; Engineering","score_opus":0.16611818676336448,"score_gpt":0.37562812197963663,"score_spread":0.20950993521627215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107103889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035662958,0.98453164,0.000074108706,0.0024127176,0.0023172658,0.008117751,0.0018714155,0.00024774147,0.00007074102],"genre_scores_gemma":[0.0022229978,0.98782164,0.00029720186,0.00012278363,0.0010124695,0.004612209,0.0032263976,0.00022019958,0.00046412268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937734,0.00036714954,0.0011885996,0.0018057977,0.001341507,0.0015235435],"domain_scores_gemma":[0.9955438,0.0004167237,0.00040225775,0.0014893373,0.00017518364,0.001972706],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00039542184,0.0014490952,0.0027744754,0.00053124863,0.00043552634,0.00013694829,0.0008528505,0.0001805983,0.0004564276],"category_scores_gemma":[0.00025569834,0.0008907869,0.0011930682,0.0011043899,0.00011202372,0.0001225487,0.00035602576,0.0015706297,0.0006810061],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003234513,0.00093097857,0.0004299562,0.0030933702,0.0009103858,0.00010046551,0.0006235029,0.000044213237,6.1978295e-7,0.000032484164,0.0067503843,0.9867602],"study_design_scores_gemma":[0.0019151884,0.000092071314,0.0031812743,0.019012125,0.0007273949,0.000005484567,0.000021238477,0.0003357101,0.000023603106,0.00011973949,0.97369444,0.0008717243],"about_ca_topic_score_codex":0.0002078936,"about_ca_topic_score_gemma":0.00004978796,"teacher_disagreement_score":0.9858885,"about_ca_system_score_codex":0.0010086356,"about_ca_system_score_gemma":0.0011274259,"threshold_uncertainty_score":0.9998259},"labels":[],"label_agreement":null},{"id":"W2111967651","doi":"10.2174/156800905774574011","title":"Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications","year":2005,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Cancer research; Biology; DNA methylation; Prostate cancer; Epigenetics; Gene silencing; Cancer; Urokinase receptor; Metastasis; Breast cancer; Tumor progression; Gene; Plasminogen activator; Gene expression; Endocrinology; Genetics","score_opus":0.03075453478558431,"score_gpt":0.35268053598754184,"score_spread":0.3219260012019575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111967651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017626556,0.98039556,0.000027438115,0.00013626118,0.00017370745,0.0011429354,0.00047616745,0.000006168292,0.000015219024],"genre_scores_gemma":[0.027675869,0.97093904,0.00006615998,0.000007430056,0.00021088518,0.0006700919,0.0003512685,0.000041084557,0.00003814388],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985365,0.00012166647,0.00047260086,0.0005244687,0.00010694077,0.00023780999],"domain_scores_gemma":[0.99916357,0.000028297243,0.0003666342,0.00024674466,0.00010872294,0.000086032975],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019002604,0.0003062181,0.00053476845,0.00014457542,0.000048283728,0.000022843282,0.00011082212,0.0001504772,0.000008617873],"category_scores_gemma":[0.000018218307,0.00026890426,0.00008823128,0.00018862098,0.000093562245,0.000006167325,0.00009335862,0.000174987,5.5171e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001116725,0.00006788604,0.007451814,0.0029430639,0.000048579008,1.5386354e-7,0.00009209773,0.000010891137,0.00053446257,0.000009619775,0.00002446048,0.98880583],"study_design_scores_gemma":[0.00047255744,0.000059282887,0.018993678,0.0032926558,0.00041094766,0.000005200171,0.0000058275323,0.00004429259,0.00046641202,0.00015661033,0.97558975,0.0005028107],"about_ca_topic_score_codex":0.000055582408,"about_ca_topic_score_gemma":0.00013848036,"teacher_disagreement_score":0.988303,"about_ca_system_score_codex":0.000052312265,"about_ca_system_score_gemma":0.00027827185,"threshold_uncertainty_score":0.99997634},"labels":[],"label_agreement":null},{"id":"W2112773270","doi":"10.2174/156800912801784857","title":"Inhibition of Protein N-Myristoylation: A Therapeutic Protocol in Developing Anticancer Agents","year":2012,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"14-3-3 protein interactions","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Myristoylation; Biology; Kinase; Cancer; Cancer research; Carcinogenesis; Cancer cell; Pharmacology; Biochemistry; Phosphorylation","score_opus":0.08981349512724712,"score_gpt":0.418618193008455,"score_spread":0.32880469788120786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112773270","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008286437,0.9517963,0.00037206014,0.00003174191,0.0006043078,0.04686669,0.000084913096,0.000013839914,0.00014729353],"genre_scores_gemma":[0.00092503347,0.7676203,0.00024384026,0.000020765638,0.00058362243,0.2300835,0.00029797122,0.00007295744,0.0001519725],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978018,0.00023288536,0.00080673385,0.00052126974,0.00024749571,0.0003898259],"domain_scores_gemma":[0.9986402,0.000012519629,0.00071947667,0.00039956183,0.00015696092,0.00007131088],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024636203,0.00042659714,0.00073468767,0.0001924012,0.00005828049,0.000018590223,0.00022748164,0.0002311354,0.0001593345],"category_scores_gemma":[0.000029342755,0.00038850878,0.00027229218,0.00030489764,0.00007718236,0.000017071181,0.00014839364,0.0003604642,0.00002192525],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037826587,0.00021075341,0.00016670047,0.02021394,0.00013898281,0.0000010853498,0.000106267755,0.000004154668,0.00052440714,0.00007868273,0.00057375454,0.9779434],"study_design_scores_gemma":[0.00034743414,0.00002266357,0.000060311457,0.01364294,0.00011097308,0.0000028085199,0.0000049046175,0.000002660003,0.00451883,0.000038636605,0.9808397,0.00040812723],"about_ca_topic_score_codex":0.000042798318,"about_ca_topic_score_gemma":0.00008896941,"teacher_disagreement_score":0.980266,"about_ca_system_score_codex":0.00033448063,"about_ca_system_score_gemma":0.00081085984,"threshold_uncertainty_score":0.9998567},"labels":[],"label_agreement":null},{"id":"W2117191309","doi":"10.2174/156800911794519743","title":"Green Tea Polyphenols as Proteasome Inhibitors: Implication in Chemoprevention","year":2011,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Tea Polyphenols and Effects","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Proteasome; Prodrug; Pharmacology; Bioavailability; Chemistry; Cancer research; Cancer cell; Apoptosis; Proteasome inhibitor; Cancer; Biochemistry; Biology; Medicine; Internal medicine","score_opus":0.05090194228805152,"score_gpt":0.3776791703544945,"score_spread":0.326777228066443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117191309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004943564,0.9915314,0.000007178965,0.00015805483,0.0016345854,0.005366699,0.000078244775,0.00014525733,0.000584243],"genre_scores_gemma":[0.0005514112,0.9916366,0.000047083377,0.000033715998,0.0018666451,0.004072333,0.00053522707,0.00014204026,0.0011149789],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99681973,0.00017613958,0.0010061269,0.00093547016,0.00037397983,0.00068856747],"domain_scores_gemma":[0.9980801,0.00004021708,0.00070053816,0.0007592205,0.00009950886,0.00032043422],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037697438,0.00073777896,0.0019590557,0.00044173357,0.000069703354,0.000028973504,0.00031303507,0.00035884505,0.00042713972],"category_scores_gemma":[0.00006858827,0.0006098318,0.00064212916,0.00060694164,0.00007148582,0.00018541982,0.00015653177,0.0010183369,0.0005102182],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022376275,0.00033039902,0.00016995484,0.031345256,0.00009763858,0.000007246493,0.0003143346,5.04151e-8,0.000011648945,0.00013140758,0.003721131,0.96384853],"study_design_scores_gemma":[0.00076563936,0.000072964904,0.00043925378,0.048816115,0.00072594936,0.000029974355,0.000009410685,0.0000022664215,0.00008660809,0.0002520487,0.9482405,0.000559241],"about_ca_topic_score_codex":0.0014924153,"about_ca_topic_score_gemma":0.00008226107,"teacher_disagreement_score":0.9632893,"about_ca_system_score_codex":0.00088402524,"about_ca_system_score_gemma":0.0009009183,"threshold_uncertainty_score":0.9996353},"labels":[],"label_agreement":null},{"id":"W2121862563","doi":"10.2174/1568009615666150105115047","title":"Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer","year":2015,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Health Authority","funders":"","keywords":"Drug delivery; Breast cancer; Monoclonal antibody; Nanotechnology; Targeted drug delivery; Nanomedicine; Drug; Cancer; Dendrimer; Liposome; Cancer therapy; Flexibility (engineering); Medicine; Pharmacology; Nanoparticle; Chemistry; Materials science; Antibody; Immunology; Internal medicine","score_opus":0.06493306173260915,"score_gpt":0.3781428014225207,"score_spread":0.31320973968991156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121862563","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0056981826,0.9729941,0.00003521103,0.0003782402,0.008001193,0.003295642,0.009329639,0.00023448562,0.000033334134],"genre_scores_gemma":[0.0015531372,0.990689,0.0002604157,0.00017839693,0.0013495123,0.0049171075,0.0006855476,0.00020664028,0.00016025927],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937285,0.00047853208,0.0016928259,0.0014824844,0.0008798633,0.0017377549],"domain_scores_gemma":[0.9966857,0.0003863502,0.00077509444,0.0007605773,0.0006704501,0.0007218718],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013304041,0.0010930662,0.0023765247,0.0005044882,0.00027078396,0.00017689649,0.0010755588,0.0002797479,0.00074592605],"category_scores_gemma":[0.00006785054,0.0009748563,0.0006854473,0.00093303993,0.00022399856,0.0006891803,0.0003645579,0.0007132959,0.00035395788],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001378983,0.0005364884,0.00012692327,0.012837705,0.0000985078,0.000014941311,0.00038086623,0.0006218715,0.00073591864,0.000054476703,0.06726806,0.9171863],"study_design_scores_gemma":[0.0015568596,0.000010177624,0.000012546771,0.009378751,0.00068007613,0.000005349785,0.000023015202,0.0010732947,0.0012933321,0.00008492308,0.9846745,0.00120715],"about_ca_topic_score_codex":0.0005274055,"about_ca_topic_score_gemma":0.000717656,"teacher_disagreement_score":0.91740644,"about_ca_system_score_codex":0.0029407756,"about_ca_system_score_gemma":0.0038890946,"threshold_uncertainty_score":0.9992702},"labels":[],"label_agreement":null},{"id":"W2135938421","doi":"10.2174/156800911796798922","title":"Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia","year":2011,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Epigenetics; Vorinostat; Histone deacetylase; Cancer research; Biology; Epigenetic therapy; Histone; Carcinogenesis; Leukemia; DNA methylation; Immunology; Cancer; Genetics; Gene expression; Gene","score_opus":0.03725352666084189,"score_gpt":0.36580973487302637,"score_spread":0.32855620821218445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135938421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019433621,0.99143237,0.00015690291,0.0000135325,0.004059831,0.0015350037,0.0004865163,0.00005576459,0.00031669528],"genre_scores_gemma":[0.0003544561,0.9931684,0.0003304467,0.00002931237,0.0018287521,0.001160957,0.0017217327,0.0003239034,0.0010820419],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99386716,0.0005323897,0.0016456649,0.0018670348,0.0005840526,0.0015036892],"domain_scores_gemma":[0.997395,0.00006801832,0.00078001077,0.001118527,0.00024405943,0.00039442518],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000528348,0.0012912763,0.0020239474,0.000402168,0.00021877725,0.00005509116,0.0011282129,0.00077958085,0.00016524734],"category_scores_gemma":[0.00023722828,0.0012623626,0.00083750347,0.00070107135,0.0004079031,0.0000211291,0.00081517623,0.0012638402,0.00024945004],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010371786,0.00042530164,0.000037231377,0.013596223,0.00054763834,0.00011439678,0.000724598,0.00013191102,0.0012158405,0.000029907964,0.12580386,0.85726935],"study_design_scores_gemma":[0.00069975405,0.000079296835,0.0000019808056,0.0064642597,0.00041697186,0.000021628288,0.000018319612,0.00002076618,0.0053115725,0.000014520714,0.9856672,0.0012836967],"about_ca_topic_score_codex":0.0003841442,"about_ca_topic_score_gemma":0.0002571752,"teacher_disagreement_score":0.8598634,"about_ca_system_score_codex":0.002414501,"about_ca_system_score_gemma":0.0037077123,"threshold_uncertainty_score":0.9999839},"labels":[],"label_agreement":null},{"id":"W2149276366","doi":"10.2174/156800906778194586","title":"Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers","year":2006,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Drug; Medicine; Intensive care medicine; Drug development; Pharmacology; Oncology","score_opus":0.05245195177791379,"score_gpt":0.39711500387024956,"score_spread":0.3446630520923358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149276366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02331028,0.9730863,0.000029226485,0.000022896273,0.0002322992,0.0014614428,0.0018411304,0.0000021500098,0.000014306987],"genre_scores_gemma":[0.0028338062,0.99232143,0.00059114466,0.0000026465307,0.0000853208,0.0015574815,0.002453181,0.000025627209,0.00012939009],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998424,0.00015568254,0.00054342294,0.00040599678,0.0002427778,0.0002281082],"domain_scores_gemma":[0.99879754,0.00009320019,0.00066140346,0.0002067375,0.00018539665,0.000055721557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020418048,0.0002850007,0.00065434957,0.00014417712,0.00008258977,0.00001659436,0.00014489297,0.000088932895,0.0000053906924],"category_scores_gemma":[0.00001905128,0.00021003296,0.00016871723,0.00012724737,0.00020270728,0.0000061327178,0.000050492643,0.00011337259,1.235232e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043126638,0.0012025185,0.00083741307,0.009587429,0.0004543791,0.0000036774998,0.0006032726,0.000020232701,0.00009400341,0.00016573798,0.0089833215,0.9780049],"study_design_scores_gemma":[0.0012061488,0.000068158886,0.00050021237,0.0021974256,0.00015113203,0.0000064708747,0.000040156072,0.000033018787,0.0006627947,0.0000048939446,0.994916,0.0002135886],"about_ca_topic_score_codex":0.00030160812,"about_ca_topic_score_gemma":0.0012050815,"teacher_disagreement_score":0.98593265,"about_ca_system_score_codex":0.000359829,"about_ca_system_score_gemma":0.0014307792,"threshold_uncertainty_score":0.85648954},"labels":[],"label_agreement":null},{"id":"W2164239756","doi":"10.2174/156800912802429292","title":"Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma","year":2012,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Stromal cell; Multiple myeloma; Syngenic; In vivo; Cancer research; Bone marrow; Tumor microenvironment; Medicine; Biology; Immunology; Tumor cells","score_opus":0.32725508467932346,"score_gpt":0.44190329542170326,"score_spread":0.1146482107423798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164239756","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002426074,0.99289757,0.0010516832,0.00006683099,0.00046955663,0.004888745,0.00030472514,0.000022559037,0.000055736775],"genre_scores_gemma":[0.0047026193,0.98966867,0.0011538841,0.000017094375,0.0003090489,0.0024719955,0.0009201568,0.000085732354,0.0006707905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972474,0.00004893872,0.00091155956,0.00043208688,0.0006812569,0.0006787835],"domain_scores_gemma":[0.9984798,0.00039038394,0.00031662747,0.0003726534,0.000113840935,0.0003267278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003307953,0.00051016826,0.0012871356,0.00026787576,0.00012833574,0.00001602713,0.000318564,0.00014891828,0.00023910406],"category_scores_gemma":[0.000031956053,0.00031256795,0.00051010255,0.000259035,0.000061663704,0.00014321273,0.000060631297,0.00041462117,0.000034293906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002250096,0.00040669463,0.00046736174,0.009295558,0.0008311376,0.0000014212521,0.0016583063,0.000023526974,5.665183e-7,0.00007170559,0.00031471025,0.986704],"study_design_scores_gemma":[0.003765169,0.000030511434,0.00070800254,0.005773851,0.0008415593,0.000003996906,0.000028533914,0.0014972279,0.00006170089,0.00012883705,0.9868537,0.00030686997],"about_ca_topic_score_codex":0.00013669868,"about_ca_topic_score_gemma":0.0004586316,"teacher_disagreement_score":0.986539,"about_ca_system_score_codex":0.0005004402,"about_ca_system_score_gemma":0.002937815,"threshold_uncertainty_score":0.99993265},"labels":[],"label_agreement":null},{"id":"W2327659954","doi":"10.2174/156800911794519770","title":"Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor","year":2011,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Biological Research and Disease Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Clioquinol; Proteasome inhibitor; Proteasome; Pharmacology; Chemistry; Extracellular; Intracellular; Mechanism of action; Prodrug; Cancer research; Biochemistry; Medicine; In vitro","score_opus":0.07753226772495421,"score_gpt":0.3724427619954073,"score_spread":0.2949104942704531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327659954","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016476531,0.9959395,0.000023243376,0.0000327127,0.0008460218,0.0016579295,0.0009722731,0.000027777736,0.000335782],"genre_scores_gemma":[0.0007554147,0.99502504,0.0000306821,0.000036188914,0.0013573342,0.0018533644,0.000375179,0.00005428883,0.0005124993],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722904,0.00014577735,0.00049151486,0.0011033936,0.00031088004,0.0007193875],"domain_scores_gemma":[0.9986332,0.00002217075,0.00026505927,0.00044799928,0.00015398569,0.00047759918],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024813926,0.00063989824,0.0010230087,0.00010584345,0.00016582462,0.00005220224,0.0004326931,0.00034969937,0.00007949809],"category_scores_gemma":[0.00017175257,0.0004539509,0.00040791664,0.000116847834,0.00027608077,0.000006432537,0.0009825414,0.00054406835,0.000044708053],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008073472,0.000227787,0.00011451881,0.0073771453,0.00033685204,0.000005260819,0.00002810467,7.557982e-8,0.00012539768,0.00006769784,0.011698951,0.9799375],"study_design_scores_gemma":[0.0004936871,0.00012866606,0.000051430234,0.0023897851,0.00020679676,0.000008154555,0.000012768195,3.2846435e-7,0.00015465701,0.000028807128,0.9959547,0.0005702094],"about_ca_topic_score_codex":0.000040232902,"about_ca_topic_score_gemma":0.00005612663,"teacher_disagreement_score":0.98425573,"about_ca_system_score_codex":0.00008636541,"about_ca_system_score_gemma":0.0006049183,"threshold_uncertainty_score":0.9997912},"labels":[],"label_agreement":null},{"id":"W2422973035","doi":"10.2174/1568009615666150616123548","title":"Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous","year":2015,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Drug delivery; Medicine; Blood–brain barrier; Glioblastoma; Chemotherapy; Radiation therapy; Brain tumor; Central nervous system; Surgery; Pathology; Internal medicine; Cancer research","score_opus":0.055808800274475975,"score_gpt":0.3625731993795175,"score_spread":0.3067643991050415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2422973035","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007353997,0.99089724,0.000011716534,0.0007685719,0.0037501547,0.0027440493,0.0006349867,0.00010948011,0.0003484098],"genre_scores_gemma":[0.0011714229,0.99343294,0.000065251,0.0001410485,0.0025328433,0.0018644911,0.00048696704,0.000118562886,0.00018645193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99716985,0.00013662483,0.00061068806,0.0006910377,0.00068949955,0.0007023062],"domain_scores_gemma":[0.99830145,0.00006367618,0.00024165628,0.0006378307,0.00027765802,0.0004777038],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020529365,0.00073471665,0.0017341302,0.00016204473,0.00014520346,0.00012731215,0.0003656386,0.00015521061,0.000317799],"category_scores_gemma":[0.000009385432,0.00041600163,0.0006741992,0.0003338071,0.00006288402,0.00009174872,0.000087364475,0.00040321282,0.00038127272],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004036027,0.00035103428,0.00014271683,0.008102519,0.00066783925,0.000058135192,0.00045533574,0.000052522126,4.205395e-7,0.0001636839,0.09594886,0.89401656],"study_design_scores_gemma":[0.00087862246,0.00007112141,0.00037037852,0.012214372,0.0016692594,0.000078193625,0.00019439202,0.00001989583,0.0000038896223,0.000003860702,0.984099,0.0003970357],"about_ca_topic_score_codex":0.0004304795,"about_ca_topic_score_gemma":0.00011002368,"teacher_disagreement_score":0.89361954,"about_ca_system_score_codex":0.0015163054,"about_ca_system_score_gemma":0.0018587414,"threshold_uncertainty_score":0.9998292},"labels":[],"label_agreement":null},{"id":"W2786620549","doi":"10.2174/1568009617666170206111609","title":"Oncolytic Viruses: The Best is Yet to Come","year":2018,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Canadian Institutes of Health Research","keywords":"Oncolytic virus; Virotherapy; Tumor microenvironment; Medicine; Immune system; Immune modulation; Immunology","score_opus":0.09197668856040245,"score_gpt":0.4374924473297759,"score_spread":0.34551575876937346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786620549","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043124828,0.9943194,0.000013078792,0.00021568045,0.0023085584,0.0016132598,0.00082232524,0.000018586054,0.0002578726],"genre_scores_gemma":[0.000046773624,0.9932629,0.000015348516,0.0008667113,0.0024218725,0.001151564,0.00024339417,0.00013500513,0.0018564501],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969717,0.0003178885,0.0005339653,0.000970936,0.0004709102,0.00073460006],"domain_scores_gemma":[0.997797,0.000041908075,0.00024793186,0.0013931409,0.00022099617,0.00029901267],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000493642,0.00062292296,0.0009066737,0.00012895867,0.00022818273,0.00008881364,0.001507952,0.00023698442,0.00044586387],"category_scores_gemma":[0.000071235125,0.0004278973,0.0005595895,0.00039077798,0.00021951702,0.0000039509837,0.00057980564,0.0004978235,0.0013236923],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011596796,0.00010372898,0.000008212947,0.0022279276,0.00029804552,0.0000017693676,0.00010789063,0.0000019171416,0.0001237201,0.000002346,0.2556629,0.7413456],"study_design_scores_gemma":[0.00021469468,0.00050149235,4.5364087e-7,0.0028702803,0.00022872322,0.00000349666,0.00001335992,0.0000020525617,0.002157061,0.000010243904,0.99347425,0.00052386837],"about_ca_topic_score_codex":0.000052997024,"about_ca_topic_score_gemma":0.00036121096,"teacher_disagreement_score":0.7408217,"about_ca_system_score_codex":0.00023785184,"about_ca_system_score_gemma":0.0013263145,"threshold_uncertainty_score":0.9998173},"labels":[],"label_agreement":null},{"id":"W2922582842","doi":"10.2174/1568009619666190326120833","title":"Inhibition of PI3K/mTOR Pathways with GDC-0980 in Pediatric Leukemia: Impact on Abnormal FLT-3 Activity and Cooperation with Intracellular Signaling Targets","year":2019,"lang":"en","type":"article","venue":"Current Cancer Drug Targets","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"PI3K/AKT/mTOR pathway; Protein kinase B; Leukemia; Phosphorylation; Pharmacology; Kinase; IC50; Cancer research; Chemistry; Apoptosis; Medicine; In vitro; Internal medicine; Biochemistry","score_opus":0.008210147615025337,"score_gpt":0.24383970911800662,"score_spread":0.23562956150298128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922582842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990449,0.007826734,0.0006187933,0.000027938668,0.00032889028,0.0005611595,0.00010815676,0.000017721093,0.00006160541],"genre_scores_gemma":[0.99808663,0.0010331954,0.00012224962,0.000027772825,0.00040904726,0.0000871291,0.00016381094,0.000047681675,0.00002247015],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829346,0.00009971584,0.00028429288,0.00061239064,0.00030872313,0.00040142442],"domain_scores_gemma":[0.99909455,0.000029184443,0.00027623575,0.0002944259,0.00018460603,0.00012100509],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027036967,0.0003537703,0.00035051777,0.00013648979,0.00006506102,0.000030505043,0.00011740294,0.00014361004,0.000054497476],"category_scores_gemma":[0.0000179507,0.00027681005,0.00006364526,0.00023491363,0.00007778221,0.000041125626,0.000058140162,0.00033564123,0.000004315196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018874934,0.00022781033,0.10934989,0.00039201503,0.00007339587,0.000009245427,0.0004539098,0.035225485,0.8482951,0.000017586175,0.0003507742,0.0037173152],"study_design_scores_gemma":[0.002688359,0.0012391737,0.01914451,0.00030681078,0.00006387129,0.000006270041,0.000042358344,0.001384489,0.9742278,0.000010744189,0.0003462427,0.000539399],"about_ca_topic_score_codex":0.00015499207,"about_ca_topic_score_gemma":0.00017038232,"teacher_disagreement_score":0.1259327,"about_ca_system_score_codex":0.00027815433,"about_ca_system_score_gemma":0.00060090097,"threshold_uncertainty_score":0.9999684},"labels":[],"label_agreement":null},{"id":"W2987452154","doi":"10.2174/1568009619666191111153049","title":"In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors","year":2019,"lang":"en","type":"article","venue":"Current Cancer Drug Targets","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Receptor tyrosine kinase; Insulin-like growth factor 1 receptor; Cancer research; Biology; Receptor; Growth factor receptor; Growth factor; Genetics","score_opus":0.005075892739689982,"score_gpt":0.23635760263322517,"score_spread":0.2312817098935352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987452154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99263257,0.0059967153,0.00004134755,0.00005862251,0.0008648919,0.0003098003,0.00007279444,0.000011598652,0.000011674763],"genre_scores_gemma":[0.99860406,0.000652336,0.00009065757,0.000024428358,0.00031376546,0.000042820837,0.00023656139,0.000017301723,0.000018051507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870956,0.000079104924,0.0004109404,0.00037112404,0.00014775427,0.00028152956],"domain_scores_gemma":[0.9995438,0.0000073635674,0.00016217156,0.0001360932,0.0000692194,0.00008135944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013760781,0.00017200835,0.00023227544,0.000080532445,0.000030162568,0.000024652809,0.00006787928,0.000104208724,0.000010846194],"category_scores_gemma":[0.000012543849,0.00017405048,0.000057975973,0.00014477197,0.000069424015,0.000018410225,0.00005644922,0.00015221971,0.0000023511623],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006123783,0.00010744642,0.1721413,0.0008646672,0.000012051563,0.0000050393605,0.000227401,0.0027943403,0.82081145,0.000012905972,0.00031929096,0.0020917025],"study_design_scores_gemma":[0.0034140225,0.00011783101,0.13806906,0.00048698782,0.0000265574,0.00001336929,0.0001656063,0.0067616915,0.850299,0.000058817826,0.0001382699,0.0004487619],"about_ca_topic_score_codex":0.00011295619,"about_ca_topic_score_gemma":0.000046416822,"teacher_disagreement_score":0.03407224,"about_ca_system_score_codex":0.00009744832,"about_ca_system_score_gemma":0.00017321769,"threshold_uncertainty_score":0.70975727},"labels":[],"label_agreement":null},{"id":"W3159431400","doi":"10.2174/1568009621666210504085527","title":"Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib","year":2021,"lang":"en","type":"article","venue":"Current Cancer Drug Targets","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Carfilzomib; Proteasome inhibitor; Rhabdomyosarcoma; Cancer research; Pediatric cancer; Cytotoxic T cell; Medicine; Cisplatin; Cytotoxicity; Proteasome; Pharmacology; Cancer; Chemotherapy; In vitro; Multiple myeloma; Sarcoma; Chemistry; Immunology; Internal medicine; Pathology","score_opus":0.012103346587631111,"score_gpt":0.26819470091373687,"score_spread":0.25609135432610575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159431400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95494694,0.04320648,0.00017688629,0.00045363986,0.00041019765,0.0005010557,0.0001749959,0.000013745315,0.00011605979],"genre_scores_gemma":[0.9957514,0.0024538664,0.00008849859,0.00012741654,0.0007941978,0.00032564095,0.00023551015,0.0000223133,0.00020115182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866486,0.00014108115,0.00025010313,0.0004575342,0.0001697939,0.00031664674],"domain_scores_gemma":[0.9994535,0.000011627564,0.000107144115,0.00023848783,0.00009264031,0.000096593736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022013517,0.00019380756,0.00018004542,0.000034240755,0.00011552515,0.000038012844,0.0001329252,0.00007958611,0.000040914052],"category_scores_gemma":[0.00007822403,0.00016181954,0.00006019895,0.00017095072,0.000056493474,0.000010347388,0.00015984087,0.00021529163,0.000004062339],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014086475,0.0003851541,0.20350337,0.00048027263,0.00004573256,0.000012501601,0.0010742275,0.00053413364,0.7519463,0.00008159014,0.029551128,0.012244725],"study_design_scores_gemma":[0.0009582663,0.000044442037,0.027880164,0.00005579359,0.00001721951,0.0000081469325,0.00007124521,0.0006223249,0.9437935,0.0003623413,0.025786944,0.00039964748],"about_ca_topic_score_codex":0.00003754773,"about_ca_topic_score_gemma":0.00008807059,"teacher_disagreement_score":0.19184716,"about_ca_system_score_codex":0.000041923908,"about_ca_system_score_gemma":0.00020945624,"threshold_uncertainty_score":0.6598809},"labels":[],"label_agreement":null},{"id":"W4206024180","doi":"10.2174/1568009622666211231140623","title":"The Potential of Natural Products in the Treatment of Triple-negative Breast Cancer","year":2021,"lang":"en","type":"article","venue":"Current Cancer Drug Targets","topic":"Curcumin's Biomedical Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Infection and Immunity; University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Triple-negative breast cancer; Natural (archaeology); Breast cancer; Medicine; Cancer; Internal medicine; Biology","score_opus":0.010211364303566737,"score_gpt":0.2927029449318295,"score_spread":0.2824915806282628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206024180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.892844,0.096072644,0.000031637588,0.00840838,0.0013829134,0.0005870226,0.0006320325,0.0000038402336,0.00003751523],"genre_scores_gemma":[0.9871562,0.0116234105,0.000038313232,0.00003322259,0.00041214842,0.00033694954,0.0001245065,0.00000805764,0.0002671791],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990528,0.00008189459,0.0002329747,0.00026615255,0.00018577352,0.00018040455],"domain_scores_gemma":[0.99924874,0.000023719678,0.00013373907,0.00033553297,0.00022966768,0.000028610995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008759313,0.00011863302,0.00014326973,0.000016768106,0.000079148835,0.000010173998,0.00021494941,0.000034071876,0.000021259395],"category_scores_gemma":[0.000033557557,0.000067707,0.00008699862,0.00025622657,0.00026408824,0.0000027991255,0.00004469155,0.000074551404,7.758286e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037275755,0.001976797,0.005553901,0.00017196502,0.0003312911,0.0000041189846,0.002767768,0.000058482186,0.6228556,0.000292671,0.022846203,0.34276843],"study_design_scores_gemma":[0.0014418212,0.00006459381,0.050298586,0.000054899654,0.00007933336,0.000007704548,0.00048785142,0.00007884862,0.7306086,0.00017957177,0.21652766,0.0001705237],"about_ca_topic_score_codex":0.0003010564,"about_ca_topic_score_gemma":0.0009815464,"teacher_disagreement_score":0.3425979,"about_ca_system_score_codex":0.000050369654,"about_ca_system_score_gemma":0.00038815997,"threshold_uncertainty_score":0.27610114},"labels":[],"label_agreement":null},{"id":"W4220827996","doi":"10.2174/1568009622666220317091723","title":"Current Treatment and Future Trends of Immunotherapy in BreastCancer","year":2022,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Immunotherapy; Medicine; Breast cancer; Clinical trial; Metastatic breast cancer; Oncology; Cancer; Immune checkpoint; Disease; Cancer immunotherapy; Blockade; Internal medicine","score_opus":0.04692936036399204,"score_gpt":0.3792937953587975,"score_spread":0.33236443499480545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220827996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012245966,0.9929475,6.345275e-7,0.00021361948,0.004613942,0.0010974698,0.0007638476,0.00003853425,0.00020196495],"genre_scores_gemma":[0.000022085029,0.9961995,0.000012797882,0.000026210995,0.0012136525,0.0015870902,0.0005642402,0.0001045556,0.0002698708],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694103,0.0002036079,0.0010831147,0.00080637657,0.00040068958,0.000565184],"domain_scores_gemma":[0.99845606,0.00007340273,0.0006654023,0.000601541,0.00004285938,0.00016074005],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002671858,0.0008114536,0.0026920624,0.00079615007,0.000087060944,0.000017957327,0.00023769362,0.00014875719,0.003986042],"category_scores_gemma":[0.000003137934,0.00060731976,0.00093783473,0.0010287379,0.00015167221,0.00007227362,0.00007792885,0.0006733426,0.0000025922732],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054418773,0.000608685,0.00029619617,0.009514443,0.00057523244,0.0000070681413,0.0006527573,2.5737518e-7,0.0000017397307,0.000011840647,0.0021600153,0.9856276],"study_design_scores_gemma":[0.003566162,0.00021868914,0.0005500664,0.011065129,0.00073757174,0.000033564946,0.0000472106,0.0000021650926,0.000004966016,0.0000046642385,0.9832665,0.0005033271],"about_ca_topic_score_codex":0.00047265098,"about_ca_topic_score_gemma":0.00017954146,"teacher_disagreement_score":0.98512423,"about_ca_system_score_codex":0.002129476,"about_ca_system_score_gemma":0.0013198279,"threshold_uncertainty_score":0.99963784},"labels":[],"label_agreement":null}]}